Therefore, we suggest the systematic use of the DETECT algorithm in all patients with SSc, regardless of disease duration, NT-proBNP, and DLCO levels, to minimize the number of PAH missed diagnoses but also to stratify PAH risk and management in patients with SSc according to the results of DETECT algorithm (i.e., indication to echocardiography for Step 2 examination only if indicated). This evidence concerns the gene NPPB and systemic sclerosis.